Defunct Company
Total Trials
7
As Lead Sponsor
5
As Collaborator
2
Total Enrollment
162
NCT01867645
The Impact of IVIG Treatment on Critical Illness Polyneuropathy and/or Myopathy in Patients With MOF and SIRS/Sepsis
Phase: Phase 1
Role: Collaborator
Start: Dec 31, 2004
Completion: Apr 30, 2011
NCT02015481
Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients
Phase: Phase 2
Role: Lead Sponsor
Start: Feb 28, 2014
Completion: Apr 30, 2016
NCT02147886
Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease
Start: Jul 31, 2014
Completion: Nov 30, 2016
NCT02328482
Continuation Protocol to Protocol BBCO-001
Phase: Phase 3
Start: Jan 31, 2015
Completion: Dec 31, 2017
NCT02725957
A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects
Start: Mar 31, 2016
Completion: Aug 31, 2016
NCT04226924
Treatment of Oculopharyngeal Muscular Dystrophy With Trehalose
Start: Jun 15, 2017
Completion: Aug 15, 2018
NCT03311932
A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female Subjects
Start: Apr 16, 2018
Completion: Jul 13, 2018